Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists

@article{Poyurovsky2020TreatmentOA,
  title={Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists},
  author={M. Poyurovsky and Abraham Weizman},
  journal={Drugs},
  year={2020},
  volume={80},
  pages={871 - 882}
}
  • M. Poyurovsky, Abraham Weizman
  • Published 2020
  • Medicine
  • Drugs
  • Akathisia is one of the most prevalent and distressing adverse effects associated with antipsychotic drug treatment. Propranolol, a non-selective beta-adrenergic receptor antagonist, is currently considered a first-line treatment for antipsychotic-induced akathisia (AIA). Surprisingly, the evidence for its anti-akathisia effect is modest. Propranolol’s side effects (e.g. orthostatic hypotension, bradycardia), contraindications (e.g. asthma) and increased complexity in titration schedules limit… CONTINUE READING
    1 Citations

    References

    SHOWING 1-10 OF 73 REFERENCES
    Treatment of Neuroleptic-Induced Akathisia With the 5-HT2A Antagonist Trazodone
    • 20
    Lack of efficacy of the 5-HT3 receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia.
    • 7
    Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin.
    • 88
    SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment
    • R. Lane
    • Psychology, Medicine
    • Journal of psychopharmacology
    • 1998
    • 185
    The Role of Serotonin in Antipsychotic Drug Action
    • H. Meltzer
    • Psychology, Medicine
    • Neuropsychopharmacology
    • 1999
    • 657
    • PDF
    5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis.
    • 24
    • PDF
    Serotonergic agents in the treatment of acute neuroleptic‐induced akathisia: open‐label study of buspirone and mianserin
    • 25
    Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study.
    • 66